Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Study of Il-12 Agonists in Macrophages From Patients With Healing and Non-Healing Forms of Cutaneous Leishmaniasis



Tolouei S1, 4 ; Hejazi SH2 ; Hasheminia SJ3 ; Arjmand R1, 4 ; Khamesipour A5 ; Nilforoushzadeh MA6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Skin Disease and Leishmaniasis Research Center AND Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Isfahan Medical School Published:2013

Abstract

Background: Cutaneous leishmaniasis (CL) is a self-healing disease; however, due to some reasons, in a few cases the lesion develops to a non-healing form of disease. The initial encounter of Leishmania with its host's innate immune system is important in the outcome of infection. Although, tremendous data is available in murine model of leishmaniasis but immunological surrogate marker(s) of healing and protection in human is not yet well-defined. In this study, the level of IL-23 and IL-27 produced by peripheral blood derived macrophages from patients with healing or non-healing form of cutaneous leishmaniasis lesion were determined to explore whether IL-23 or IL-27 plays a protection role in healing process of cutaneous lesions induced by Leishmania major (L. major). Methods: 26 six patients resident in Isfahan Province, Iran, with healing or non-healing forms of cutaneous leishmaniasis caused by L. major were selected. In-vitro productions of IL-23 and IL-27 by peripheral blood derived macrophages, before and after stimulation with live L. major (MRHO/IR/75/ER) promastigotes were evaluated in these two groups and control group using the enzyme-linked immunosorbent assay (ELISA) method. Findings: The mean difference production of IL-23 and IL-27 from macrophages of patients with healing form of lesion was significantly higher than patients with non-healing form. The levels of IL-23 and IL-27 in culture supernatants before and after stimulation in healing form of disease was significantly higher than non-healing form (P < 0.001). Conclusion: It seems that IL-12 agonists might play a protection role in human leishmaniasis and further studies are needed to understand the role of these cytokine in cutaneous leishmaniasis.
Related Docs
View other Related Docs
1. Il-23 and Il-27 Levels in Macrophages Collected From Peripheral Blood of Patients With Healing Vs Non-Healing Form of Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
2. Tlr2 and Tlr4 in Cutaneous Leishmaniasis Caused by Leishmania Major, Scandinavian Journal of Immunology (2013)
3. Comparison of Pro-Inflammatory Cytokines of Non-Healing and Healing Cutaneous Leishmaniasis, Scandinavian Journal of Immunology (2017)
4. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
5. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
6. Regulatory T-Cell Profile in Early and Late Lesions of Cutaneous Leishmaniasis Due to Leishmania Major, Journal of Isfahan Medical School (2014)
7. Evaluation of Il-12Rb1, Il-12B, Cxcr-3 and Il-17A Expression in Cases Affected by a Non-Healing Form of Cutaneous Leishmaniasis: An Observational Study Design, BMJ Open (2017)
8. Comparison of Immune Regulatory Factors in Acute and Chronic Lesions of Cutaneous Leishmaniasis Due to Leishmania Major, Journal of Research in Medical Sciences (2014)
Experts (# of related papers)
View all Related Experts
Seyed Hossein Hejazi (46)
Ali Asilian (13)
Other Related Docs
9. Exposure to Leishmania Major Modulates the Proportion of Cd4+ T Cells Without Affecting Cellular Immune Responses, Microbiology and Immunology (2007)
10. Regulatory T-Cell Profile in Early and Late Lesions of Cutaneous Leishmaniasis Due to Leishmania Major, Journal of Research in Medical Sciences (2012)
11. Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime, Journal of Isfahan Medical School (2012)
12. Cutaneous Leishmaniasis Reinfection: Skin Disease and Leishmaniasis Research Center, Isfahan, Iran, Journal of Isfahan Medical School (2015)
13. The Comparison of the Ifn-ɤ, Tnf-Α and Il-10 Cytokines in Healing and Non-Healing Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2021)
14. Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime, Journal of Isfahan Medical School (2012)
15. Immune Response Measured in Human Volunteers Vaccinated With Autoclaved Leishmania Major Vaccine Mixed With Low Dose of Bcg, Clinical and Experimental Immunology (2003)
16. Identification of Leishmania Isolates From Healing and Nonhealing Cutaneous Leishmaniasis Patients Using Internal Transcribed Spacer Region Pcr, Jundishapur Journal of Microbiology (2014)
17. Comparison of Protein Profile of Killed and Autoclaved Leishmania Major Using Polyacrylamide Gel Electrophoresis, Journal of Isfahan Medical School (2013)
18. Comparing the Effects of Topical Miltefosine and Glucantime in Treatment of Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2014)
19. The Effects of Prednisolone and Mometasone on Wound Healing Caused by Leishmania Major in Balb/C Mice, Journal of Isfahan Medical School (2020)
20. Il-27 Plasma Level in Relapsing Remitting Multiple Sclerosis Subjects: The Double-Faced Cytokine, Journal of Immunoassay and Immunochemistry (2016)
21. Comparison of Three Different Therapies for Cutaneous Leishmaniasis and Identification of the Etiologic Isolates in Isfahan, Iran, Archives of Iranian Medicine (2020)
22. Reevaluating Leishmanin Skin Test As a Marker for Immunity Against Cutaneous Leishmaniasis, International Journal of Dermatology (2013)
23. Isolation of Bacteria Causing Secondary Bacterial Infection in the Lesions of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2008)
24. Evaluation of Leishmanin Skin Test and Its Relationship With the Clinical Form and Duration of Cutaneous Leishmaniasis, Dermatology Online Journal (2006)
25. Evaluation of Leishmanin Skin Test Reaction in Different Variants of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2013)
26. Recombinant C-Reactive Protein: A Potential Candidate for the Treatment of Cutaneous Leishmaniasis of Balb/C Mice Caused by Leishmania Major, Acta Parasitologica (2021)
27. Pcr-Rflp Diagnosis and Characterization of Leishmania Species Causing Human Cutaneous Leishmaniasis and Evaluation of Treatment Times With Glucantime in These Patients, Tropical Biomedicine (2016)
28. A Lentiviral Vaccine Expressing Kmp11-Haspb Fusion Protein Increases Immune Response to Leishmania Major in Balb/C, Parasitology Research (2018)
29. Epidemiological Aspects of Cutaneous Leishmaniasis in Iran, Archives of Clinical Infectious Diseases (2015)
30. Comparison of Intralesionally Injected Zinc Sulfate With Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, Dermatology (2004)
31. Therapeutic Effect of Topical Tamoxifen in Murine Cutaneous Leishmaniasis Caused by Leishmania Major, Antimicrobial Agents and Chemotherapy (2024)
32. A Randomised, Double-Blind, Controlled Trial of a Killed L. Major Vaccine Plus Bcg Against Zoonotic Cutaneous Leishmaniasis in Iran, Vaccine (1999)
33. Combinatorial Delivery of Antigen and Tlr Agonists Via Plga Nanoparticles Modulates Leishmania Major-Infected-Macrophages Activation, Biomedicine and Pharmacotherapy (2021)
34. Nramp1 Gene Polymorphisms and Cutaneous Leishmaniasis: An Evaluation on Host Susceptibility and Treatment Outcome, Journal of Vector Borne Diseases (2016)
35. Comparative Molecular Epidemiology of Leishmania Major and Leishmania Tropica by Pcr-Rflp Technique in Hyper Endemic Cities of Isfahan and Bam, Iran, Case Reports and Clinical Practice Review (2010)
36. Bacterial Superinfection in Zoonotic Cutaneous Leishmaniasis, Medical Science Monitor (2012)
37. Electrocardiographic Changes in Patients With Cutaneous Leishmaniasis Treated With Systemic Glucantime, Annals of the Academy of Medicine Singapore (2008)
38. The Efficacy of 5% Trichloroacetic Acid Cream in the Treatment of Cutaneous Leishmaniasis Lesions, Journal of Dermatological Treatment (2012)
39. Molecular Identification and Phylogenetic Classification of Leishmania Spp. Isolated From Human Cutaneous Leishmaniasis in Iran: A Cross-Sectional Study, Iranian Journal of Parasitology (2018)
40. A Comparison Between the Effects of Glucantime, Topical Trichloroacetic Acid 50% Plus Glucantime, and Fractional Laser Plus Glucantime on Cutaneous Leishmaniasis Lesions, Journal of Isfahan Medical School (2013)
41. The Study of the Inhibitory Effects of Aqueous and Ethanolic Extracts of Ziziphora Tenuior L. on the Proliferation of Leishmania Major Amastigotes, Iranian Journal of Dermatology (2018)
42. The Skin Side Effects of Topical Glucantime in Patients With Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2015)
43. Effect of Adjunctive Topical Liposomal Azithromycin on Systemic Azithromycin on Old World Cutaneous Leishmaniasis: A Pilot Clinical Study, Iranian Journal of Pharmaceutical Research (2021)
44. Effect of Topical Honey Application Along With Intralesional Injection of Glucantime in the Treatment of Cutaneous Leishmaniasis, BMC Complementary and Alternative Medicine (2007)
45. Locked Nucleic Acid -Anti- Let-7A Induces Apoptosis and Necrosis in Macrophages Infected With Leishmania Major, Microbial Pathogenesis (2018)
46. In Vitro Study of the Leishmanicidal Activity of Perovskia Abrotanoides Terpenoid-Rich Fractions Against Leishmania Major (Mrho/Ir/75/Er), Advanced Biomedical Research (2023)
47. Study of Therapeutic Effect of Different Concentrations of Imatinib on Balb/C Model of Cutaneous Leishmaniasis, AIMS Microbiology (2020)
48. Comparative Effect of Topical Trichloroacetic Acid and Intralesional Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, International Journal of Pharmacology (2006)
49. Comparative Molecular Epidemiology of Leishmania Major and Leishmania Tropica by Pcr-Rflp Technique in Hyper Endemic Cities of Isfahan and Bam, Iran, Medical Science Monitor (2010)
50. Anti-Leishmaniasis Effect of Staphylococcus Aureus Protein a on the Size of the Lesion and Parasitic Load, Advanced Biomedical Research (2023)